BioCentury
ARTICLE | Company News

PTAB upholds Gilenya patent

July 20, 2018 5:30 PM UTC

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board upheld claims 1-6 of U.S. Patent No. 9,187,405 covering multiple sclerosis drug Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN). PTAB instituted a review of the patent last year, following IPR challenges from Apotex Inc. (Toronto, Ontario) and other generics makers.

The patent expires in 2027...

BCIQ Company Profiles

Novartis AG